Interference of lupus anticoagulant causing antiprothrombin and anti–beta-2-glycoprotein I antibodies on international normalized ratio measurements: comparative analysis of international normalized ratio methods
Authors:
Open Access
- 8 June 2024
- journal article
- research article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 8 (5) , 102470
Abstract
No abstract availableKeywords
Funding Information
- Novartis
- CSL Behring
This publication has 49 references indexed in Scilit:
- Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid SyndromesJACC, 2022
- Warfarin monitoring and interference by lupus anticoagulant in patients with antiphospholipid syndromeThrombosis Research, 2022
- The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generationThrombosis Research, 2018
- The Lupus Anticoagulant ParadoxSeminars in Thrombosis and Hemostasis, 2017
- Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndromeThrombosis Research, 2015
- Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastinsBritish Journal of Haematology, 2001
- Complexes of anti‐prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfacesBritish Journal of Haematology, 2001
- Quantification of Lupus Anticoagulants in Clinical Samples Using Anti- β2GP1 and Anti-Prothrombin Monoclonal AntibodiesThrombosis and Haemostasis, 2001
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975
- THROMBOTEST A NEW METHOD FOR CONTROLLING ANTICOAGULANT THERAPYThe Lancet, 1959